AARP tells members the Bridge is delivering major savings as open enrollment approaches

AARP's weekly member video, released for the week of September 11, 2026, led with news that the Medicare GLP-1 Bridge program has saved beneficiaries about $216 million since it launched in July ^[1]. More than 500,000 people are now enrolled in the 18-month pilot, paying $50 a month for drugs including Wegovy, Foundayo and Zepbound ^[1].

The Bridge program lets Medicare beneficiaries get these drugs without a qualifying diagnosis such as type 2 diabetes or sleep apnea, conditions normally required for coverage ^[1]. That is a notable change from standard Medicare Part D rules, which generally do not pay for GLP-1 drugs used only for weight loss. According to the health research group KFF, cited in the AARP video, this expanded access could eventually affect an estimated 3.8 million Medicare beneficiaries who do not currently qualify for coverage under Part D ^[1].

The AARP report frames the $216 million figure and the 500,000-enrollee count as coming from the White House ^[1]. The video does not break down how enrollment has changed week to week, so it is not yet known from this source exactly how fast the program is growing or whether enrollment has continued past the 500,000 mark reported here.

Why it matters for patients

For Medicare beneficiaries who do not have a qualifying diagnosis like type 2 diabetes or sleep apnea, the Bridge program is one of the few paths to GLP-1 coverage at a fixed $50 monthly cost rather than paying full list price out of pocket ^[1]. That matters because standard Part D plans typically will not cover semaglutide or tirzepatide products, such as Wegovy or Zepbound, when they are prescribed only for weight management ^[1].

The program is temporary. It is described as an 18-month pilot, which means the $50 pricing and no-diagnosis-required access are not guaranteed to continue indefinitely ^[1]. Beneficiaries weighing whether to start or continue treatment through this pathway may want to keep that time limit in mind, since coverage terms could change once the pilot period ends.

The KFF estimate of 3.8 million potentially eligible beneficiaries shows the scale of demand this program could eventually serve, but only a fraction of that group — a little over 500,000 people as of the report — has enrolled so far ^[1]. That gap suggests many eligible people may not yet know the program exists or how to access it, though the source material does not explain why enrollment has not grown faster.

What happens next

The AARP video does not give a specific end date for the pilot beyond describing it as 18 months long, and it does not detail what happens to enrollees or drug pricing once that period concludes ^[1]. As Medicare's fall open enrollment season approaches, more beneficiaries are likely to compare their existing coverage against what the Bridge program offers. Whether enrollment continues to climb past 500,000, and whether the $216 million in savings grows at a similar pace, is not addressed in the available reporting and will depend on data not yet published in these sources.